De Lisle Partners LLP Uro Gen Pharma Ltd. Transaction History
De Lisle Partners LLP
- $602 Billion
- Q1 2025
A detailed history of De Lisle Partners LLP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, De Lisle Partners LLP holds 81,510 shares of URGN stock, worth $1.07 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
81,510
Previous 81,510
-0.0%
Holding current value
$1.07 Million
Previous $868 Million
3.99%
% of portfolio
0.15%
Previous 0.13%
Shares
2 transactions
Others Institutions Holding URGN
# of Institutions
142Shares Held
41.6MCall Options Held
91.4KPut Options Held
42.1K-
Ubs Asset Management Americas Inc Chicago, IL4.36MShares$57.3 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY3.83MShares$50.4 Million0.69% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.21MShares$42.1 Million0.74% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$30.3 Million0.17% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$28.8 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $299M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...